FLOWBONE is involved in the development and promotion of a revolutionary biomaterial for the minimal-invasive augmentation of fragile bones. FLOWBONE, follows a completely new treatment approach allowing fragilized bone to augment and repair itself without impeding bone mechanics or blood flow within the bone. The product can be used for both bone repair and fragility fracture prevention, and their initial focus will be targeting high risk areas such as the spine and hips. The technology is the result of 6+ years of research at EPFL is currently in the pre-clinical phase preparing for clinical trials prior to market commercialization.

News

06.09.2024 Kickfund invests at full throttle (startupticker.ch)
27.10.2022 Swiss startups take the lead on global stages (startupticker.ch)
01.09.2022 Ten startups to explore India (startupticker.ch)
24.06.2021 IMAGINE IF! Swiss winners revealed (startupticker.ch)
09.06.2021 First Venture Leaders Medtech selected (startupticker.ch)
12.05.2021 Finalists of the W. A de Vigier revealed (startupticker.ch)
06.05.2021 Flowbone triomphe aux Prix PERL 2021 (startupticker.ch)

Milestones/News

25.02.2022 FDA regulatory strategy determined
31.12.2021 Scale-up of the production to kilo-batches
01.08.2021 Submission of pre-Request for Designation to FDA
30.06.2021 Signature of exclusive patent license agreement with EPFL
31.05.2021 Validated proof-of-concept in large animals

Videos and Presentations


flowbone: local bone strengthening to prevent devastating hip fractures


Pitch Startup Champions Seed Night 2020

Player is loading...